Skip to main content
Funding round pulls in $30M for Exosome Diagnostics

A round of Series C financing led by Tiger Partners and Forbion Capital Partners pulled in $30 million for Exosome Diagnostics. The proceeds will be used for a rapid commercial expansion of the ExoDx Prostate (IntelliScore) test, as well as to commercialize oncological diagnostics, develop tests for other applications, conduct investigations into new technologies and expand the company's companion diagnostics and instrumentation arms.

Full Story: